The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Migraine Therapeutics Market Research Report 2025
Synopsis
Migraines are a family of recurrent attacks.The symptom is paroxysmal unilateral throbbing headache, accompanied by nausea, vomiting and confusion. Migraine therapeutics includes triptans, acetylcholine inhibitors/neurotoxins, ergot alkaloids, nsaids, ditan, CGRP small molecule antagonists, CGRP monoclonal antibodies, etc.
The global Migraine Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Migraine Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Migraine Therapeutics.
Report Scope
The Migraine Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Migraine Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Migraine Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan
Merck
Pfizer
Teva
Amgen
Johnson & Johnson
Endo International
GlaxoSmithKline
Impax
Abbott
Bayer
Eli Lilly
Novartis International
Ethypharm
Kowa Pharmaceuticals America
Winston Pharmaceuticals
AstraZeneca
Amirall
OptiNose
Revance Therapeutics
RedHill Biopharma
Bausch Health
NeurAxon
Biohaven Pharma
Eisai
Valeant Pharma
Segment by Type
Specific Anti-migraine Drugs
Acute Therapies
Preventative Therapies
Other
Segment by Application
Hospitals
Clinics
Household Use
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Migraine Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Migraines are a family of recurrent attacks.The symptom is paroxysmal unilateral throbbing headache, accompanied by nausea, vomiting and confusion. Migraine therapeutics includes triptans, acetylcholine inhibitors/neurotoxins, ergot alkaloids, nsaids, ditan, CGRP small molecule antagonists, CGRP monoclonal antibodies, etc.
The global Migraine Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Migraine Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Migraine Therapeutics.
Report Scope
The Migraine Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Migraine Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Migraine Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan
Merck
Pfizer
Teva
Amgen
Johnson & Johnson
Endo International
GlaxoSmithKline
Impax
Abbott
Bayer
Eli Lilly
Novartis International
Ethypharm
Kowa Pharmaceuticals America
Winston Pharmaceuticals
AstraZeneca
Amirall
OptiNose
Revance Therapeutics
RedHill Biopharma
Bausch Health
NeurAxon
Biohaven Pharma
Eisai
Valeant Pharma
Segment by Type
Specific Anti-migraine Drugs
Acute Therapies
Preventative Therapies
Other
Segment by Application
Hospitals
Clinics
Household Use
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Migraine Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Migraine Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Specific Anti-migraine Drugs
1.2.3 Acute Therapies
1.2.4 Preventative Therapies
1.2.5 Other
1.3 Market by Application
1.3.1 Global Migraine Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Household Use
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Migraine Therapeutics Market Perspective (2019-2030)
2.2 Migraine Therapeutics Growth Trends by Region
2.2.1 Global Migraine Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Migraine Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Migraine Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Migraine Therapeutics Market Dynamics
2.3.1 Migraine Therapeutics Industry Trends
2.3.2 Migraine Therapeutics Market Drivers
2.3.3 Migraine Therapeutics Market Challenges
2.3.4 Migraine Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Migraine Therapeutics Players by Revenue
3.1.1 Global Top Migraine Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Migraine Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Migraine Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Migraine Therapeutics Revenue
3.4 Global Migraine Therapeutics Market Concentration Ratio
3.4.1 Global Migraine Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Migraine Therapeutics Revenue in 2023
3.5 Migraine Therapeutics Key Players Head office and Area Served
3.6 Key Players Migraine Therapeutics Product Solution and Service
3.7 Date of Enter into Migraine Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Migraine Therapeutics Breakdown Data by Type
4.1 Global Migraine Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Migraine Therapeutics Forecasted Market Size by Type (2025-2030)
5 Migraine Therapeutics Breakdown Data by Application
5.1 Global Migraine Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Migraine Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Migraine Therapeutics Market Size (2019-2030)
6.2 North America Migraine Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Migraine Therapeutics Market Size by Country (2019-2024)
6.4 North America Migraine Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Migraine Therapeutics Market Size (2019-2030)
7.2 Europe Migraine Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Migraine Therapeutics Market Size by Country (2019-2024)
7.4 Europe Migraine Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Migraine Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Migraine Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Migraine Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Migraine Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Migraine Therapeutics Market Size (2019-2030)
9.2 Latin America Migraine Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Migraine Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Migraine Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Migraine Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Migraine Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Migraine Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Migraine Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allergan
11.1.1 Allergan Company Detail
11.1.2 Allergan Business Overview
11.1.3 Allergan Migraine Therapeutics Introduction
11.1.4 Allergan Revenue in Migraine Therapeutics Business (2019-2024)
11.1.5 Allergan Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Migraine Therapeutics Introduction
11.2.4 Merck Revenue in Migraine Therapeutics Business (2019-2024)
11.2.5 Merck Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Migraine Therapeutics Introduction
11.3.4 Pfizer Revenue in Migraine Therapeutics Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Teva
11.4.1 Teva Company Detail
11.4.2 Teva Business Overview
11.4.3 Teva Migraine Therapeutics Introduction
11.4.4 Teva Revenue in Migraine Therapeutics Business (2019-2024)
11.4.5 Teva Recent Development
11.5 Amgen
11.5.1 Amgen Company Detail
11.5.2 Amgen Business Overview
11.5.3 Amgen Migraine Therapeutics Introduction
11.5.4 Amgen Revenue in Migraine Therapeutics Business (2019-2024)
11.5.5 Amgen Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Detail
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Migraine Therapeutics Introduction
11.6.4 Johnson & Johnson Revenue in Migraine Therapeutics Business (2019-2024)
11.6.5 Johnson & Johnson Recent Development
11.7 Endo International
11.7.1 Endo International Company Detail
11.7.2 Endo International Business Overview
11.7.3 Endo International Migraine Therapeutics Introduction
11.7.4 Endo International Revenue in Migraine Therapeutics Business (2019-2024)
11.7.5 Endo International Recent Development
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Detail
11.8.2 GlaxoSmithKline Business Overview
11.8.3 GlaxoSmithKline Migraine Therapeutics Introduction
11.8.4 GlaxoSmithKline Revenue in Migraine Therapeutics Business (2019-2024)
11.8.5 GlaxoSmithKline Recent Development
11.9 Impax
11.9.1 Impax Company Detail
11.9.2 Impax Business Overview
11.9.3 Impax Migraine Therapeutics Introduction
11.9.4 Impax Revenue in Migraine Therapeutics Business (2019-2024)
11.9.5 Impax Recent Development
11.10 Abbott
11.10.1 Abbott Company Detail
11.10.2 Abbott Business Overview
11.10.3 Abbott Migraine Therapeutics Introduction
11.10.4 Abbott Revenue in Migraine Therapeutics Business (2019-2024)
11.10.5 Abbott Recent Development
11.11 Bayer
11.11.1 Bayer Company Detail
11.11.2 Bayer Business Overview
11.11.3 Bayer Migraine Therapeutics Introduction
11.11.4 Bayer Revenue in Migraine Therapeutics Business (2019-2024)
11.11.5 Bayer Recent Development
11.12 Eli Lilly
11.12.1 Eli Lilly Company Detail
11.12.2 Eli Lilly Business Overview
11.12.3 Eli Lilly Migraine Therapeutics Introduction
11.12.4 Eli Lilly Revenue in Migraine Therapeutics Business (2019-2024)
11.12.5 Eli Lilly Recent Development
11.13 Novartis International
11.13.1 Novartis International Company Detail
11.13.2 Novartis International Business Overview
11.13.3 Novartis International Migraine Therapeutics Introduction
11.13.4 Novartis International Revenue in Migraine Therapeutics Business (2019-2024)
11.13.5 Novartis International Recent Development
11.14 Ethypharm
11.14.1 Ethypharm Company Detail
11.14.2 Ethypharm Business Overview
11.14.3 Ethypharm Migraine Therapeutics Introduction
11.14.4 Ethypharm Revenue in Migraine Therapeutics Business (2019-2024)
11.14.5 Ethypharm Recent Development
11.15 Kowa Pharmaceuticals America
11.15.1 Kowa Pharmaceuticals America Company Detail
11.15.2 Kowa Pharmaceuticals America Business Overview
11.15.3 Kowa Pharmaceuticals America Migraine Therapeutics Introduction
11.15.4 Kowa Pharmaceuticals America Revenue in Migraine Therapeutics Business (2019-2024)
11.15.5 Kowa Pharmaceuticals America Recent Development
11.16 Winston Pharmaceuticals
11.16.1 Winston Pharmaceuticals Company Detail
11.16.2 Winston Pharmaceuticals Business Overview
11.16.3 Winston Pharmaceuticals Migraine Therapeutics Introduction
11.16.4 Winston Pharmaceuticals Revenue in Migraine Therapeutics Business (2019-2024)
11.16.5 Winston Pharmaceuticals Recent Development
11.17 AstraZeneca
11.17.1 AstraZeneca Company Detail
11.17.2 AstraZeneca Business Overview
11.17.3 AstraZeneca Migraine Therapeutics Introduction
11.17.4 AstraZeneca Revenue in Migraine Therapeutics Business (2019-2024)
11.17.5 AstraZeneca Recent Development
11.18 Amirall
11.18.1 Amirall Company Detail
11.18.2 Amirall Business Overview
11.18.3 Amirall Migraine Therapeutics Introduction
11.18.4 Amirall Revenue in Migraine Therapeutics Business (2019-2024)
11.18.5 Amirall Recent Development
11.19 OptiNose
11.19.1 OptiNose Company Detail
11.19.2 OptiNose Business Overview
11.19.3 OptiNose Migraine Therapeutics Introduction
11.19.4 OptiNose Revenue in Migraine Therapeutics Business (2019-2024)
11.19.5 OptiNose Recent Development
11.20 Revance Therapeutics
11.20.1 Revance Therapeutics Company Detail
11.20.2 Revance Therapeutics Business Overview
11.20.3 Revance Therapeutics Migraine Therapeutics Introduction
11.20.4 Revance Therapeutics Revenue in Migraine Therapeutics Business (2019-2024)
11.20.5 Revance Therapeutics Recent Development
11.21 RedHill Biopharma
11.21.1 RedHill Biopharma Company Detail
11.21.2 RedHill Biopharma Business Overview
11.21.3 RedHill Biopharma Migraine Therapeutics Introduction
11.21.4 RedHill Biopharma Revenue in Migraine Therapeutics Business (2019-2024)
11.21.5 RedHill Biopharma Recent Development
11.22 Bausch Health
11.22.1 Bausch Health Company Detail
11.22.2 Bausch Health Business Overview
11.22.3 Bausch Health Migraine Therapeutics Introduction
11.22.4 Bausch Health Revenue in Migraine Therapeutics Business (2019-2024)
11.22.5 Bausch Health Recent Development
11.23 NeurAxon
11.23.1 NeurAxon Company Detail
11.23.2 NeurAxon Business Overview
11.23.3 NeurAxon Migraine Therapeutics Introduction
11.23.4 NeurAxon Revenue in Migraine Therapeutics Business (2019-2024)
11.23.5 NeurAxon Recent Development
11.24 Biohaven Pharma
11.24.1 Biohaven Pharma Company Detail
11.24.2 Biohaven Pharma Business Overview
11.24.3 Biohaven Pharma Migraine Therapeutics Introduction
11.24.4 Biohaven Pharma Revenue in Migraine Therapeutics Business (2019-2024)
11.24.5 Biohaven Pharma Recent Development
11.25 Eisai
11.25.1 Eisai Company Detail
11.25.2 Eisai Business Overview
11.25.3 Eisai Migraine Therapeutics Introduction
11.25.4 Eisai Revenue in Migraine Therapeutics Business (2019-2024)
11.25.5 Eisai Recent Development
11.26 Valeant Pharma
11.26.1 Valeant Pharma Company Detail
11.26.2 Valeant Pharma Business Overview
11.26.3 Valeant Pharma Migraine Therapeutics Introduction
11.26.4 Valeant Pharma Revenue in Migraine Therapeutics Business (2019-2024)
11.26.5 Valeant Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Migraine Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Specific Anti-migraine Drugs
Table 3. Key Players of Acute Therapies
Table 4. Key Players of Preventative Therapies
Table 5. Key Players of Other
Table 6. Global Migraine Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Migraine Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Migraine Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Migraine Therapeutics Market Share by Region (2019-2024)
Table 10. Global Migraine Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Migraine Therapeutics Market Share by Region (2025-2030)
Table 12. Migraine Therapeutics Market Trends
Table 13. Migraine Therapeutics Market Drivers
Table 14. Migraine Therapeutics Market Challenges
Table 15. Migraine Therapeutics Market Restraints
Table 16. Global Migraine Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Migraine Therapeutics Market Share by Players (2019-2024)
Table 18. Global Top Migraine Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Migraine Therapeutics as of 2023)
Table 19. Ranking of Global Top Migraine Therapeutics Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Migraine Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Migraine Therapeutics Product Solution and Service
Table 23. Date of Enter into Migraine Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Migraine Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Migraine Therapeutics Revenue Market Share by Type (2019-2024)
Table 27. Global Migraine Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Migraine Therapeutics Revenue Market Share by Type (2025-2030)
Table 29. Global Migraine Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Migraine Therapeutics Revenue Market Share by Application (2019-2024)
Table 31. Global Migraine Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Migraine Therapeutics Revenue Market Share by Application (2025-2030)
Table 33. North America Migraine Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Migraine Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Migraine Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Migraine Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Migraine Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Migraine Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Migraine Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Migraine Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Migraine Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Migraine Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Migraine Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Migraine Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Migraine Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Migraine Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Migraine Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 48. Allergan Company Detail
Table 49. Allergan Business Overview
Table 50. Allergan Migraine Therapeutics Product
Table 51. Allergan Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 52. Allergan Recent Development
Table 53. Merck Company Detail
Table 54. Merck Business Overview
Table 55. Merck Migraine Therapeutics Product
Table 56. Merck Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 57. Merck Recent Development
Table 58. Pfizer Company Detail
Table 59. Pfizer Business Overview
Table 60. Pfizer Migraine Therapeutics Product
Table 61. Pfizer Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 62. Pfizer Recent Development
Table 63. Teva Company Detail
Table 64. Teva Business Overview
Table 65. Teva Migraine Therapeutics Product
Table 66. Teva Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 67. Teva Recent Development
Table 68. Amgen Company Detail
Table 69. Amgen Business Overview
Table 70. Amgen Migraine Therapeutics Product
Table 71. Amgen Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 72. Amgen Recent Development
Table 73. Johnson & Johnson Company Detail
Table 74. Johnson & Johnson Business Overview
Table 75. Johnson & Johnson Migraine Therapeutics Product
Table 76. Johnson & Johnson Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 77. Johnson & Johnson Recent Development
Table 78. Endo International Company Detail
Table 79. Endo International Business Overview
Table 80. Endo International Migraine Therapeutics Product
Table 81. Endo International Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 82. Endo International Recent Development
Table 83. GlaxoSmithKline Company Detail
Table 84. GlaxoSmithKline Business Overview
Table 85. GlaxoSmithKline Migraine Therapeutics Product
Table 86. GlaxoSmithKline Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 87. GlaxoSmithKline Recent Development
Table 88. Impax Company Detail
Table 89. Impax Business Overview
Table 90. Impax Migraine Therapeutics Product
Table 91. Impax Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 92. Impax Recent Development
Table 93. Abbott Company Detail
Table 94. Abbott Business Overview
Table 95. Abbott Migraine Therapeutics Product
Table 96. Abbott Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 97. Abbott Recent Development
Table 98. Bayer Company Detail
Table 99. Bayer Business Overview
Table 100. Bayer Migraine Therapeutics Product
Table 101. Bayer Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 102. Bayer Recent Development
Table 103. Eli Lilly Company Detail
Table 104. Eli Lilly Business Overview
Table 105. Eli Lilly Migraine Therapeutics Product
Table 106. Eli Lilly Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 107. Eli Lilly Recent Development
Table 108. Novartis International Company Detail
Table 109. Novartis International Business Overview
Table 110. Novartis International Migraine Therapeutics Product
Table 111. Novartis International Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 112. Novartis International Recent Development
Table 113. Ethypharm Company Detail
Table 114. Ethypharm Business Overview
Table 115. Ethypharm Migraine Therapeutics Product
Table 116. Ethypharm Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 117. Ethypharm Recent Development
Table 118. Kowa Pharmaceuticals America Company Detail
Table 119. Kowa Pharmaceuticals America Business Overview
Table 120. Kowa Pharmaceuticals America Migraine Therapeutics Product
Table 121. Kowa Pharmaceuticals America Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 122. Kowa Pharmaceuticals America Recent Development
Table 123. Winston Pharmaceuticals Company Detail
Table 124. Winston Pharmaceuticals Business Overview
Table 125. Winston Pharmaceuticals Migraine Therapeutics Product
Table 126. Winston Pharmaceuticals Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 127. Winston Pharmaceuticals Recent Development
Table 128. AstraZeneca Company Detail
Table 129. AstraZeneca Business Overview
Table 130. AstraZeneca Migraine Therapeutics Product
Table 131. AstraZeneca Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 132. AstraZeneca Recent Development
Table 133. Amirall Company Detail
Table 134. Amirall Business Overview
Table 135. Amirall Migraine Therapeutics Product
Table 136. Amirall Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 137. Amirall Recent Development
Table 138. OptiNose Company Detail
Table 139. OptiNose Business Overview
Table 140. OptiNose Migraine Therapeutics Product
Table 141. OptiNose Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 142. OptiNose Recent Development
Table 143. Revance Therapeutics Company Detail
Table 144. Revance Therapeutics Business Overview
Table 145. Revance Therapeutics Migraine Therapeutics Product
Table 146. Revance Therapeutics Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 147. Revance Therapeutics Recent Development
Table 148. RedHill Biopharma Company Detail
Table 149. RedHill Biopharma Business Overview
Table 150. RedHill Biopharma Migraine Therapeutics Product
Table 151. RedHill Biopharma Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 152. RedHill Biopharma Recent Development
Table 153. Bausch Health Company Detail
Table 154. Bausch Health Business Overview
Table 155. Bausch Health Migraine Therapeutics Product
Table 156. Bausch Health Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 157. Bausch Health Recent Development
Table 158. NeurAxon Company Detail
Table 159. NeurAxon Business Overview
Table 160. NeurAxon Migraine Therapeutics Product
Table 161. NeurAxon Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 162. NeurAxon Recent Development
Table 163. Biohaven Pharma Company Detail
Table 164. Biohaven Pharma Business Overview
Table 165. Biohaven Pharma Migraine Therapeutics Product
Table 166. Biohaven Pharma Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 167. Biohaven Pharma Recent Development
Table 168. Eisai Company Detail
Table 169. Eisai Business Overview
Table 170. Eisai Migraine Therapeutics Product
Table 171. Eisai Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 172. Eisai Recent Development
Table 173. Valeant Pharma Company Detail
Table 174. Valeant Pharma Business Overview
Table 175. Valeant Pharma Migraine Therapeutics Product
Table 176. Valeant Pharma Revenue in Migraine Therapeutics Business (2019-2024) & (US$ Million)
Table 177. Valeant Pharma Recent Development
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Migraine Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Migraine Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Specific Anti-migraine Drugs Features
Figure 4. Acute Therapies Features
Figure 5. Preventative Therapies Features
Figure 6. Other Features
Figure 7. Global Migraine Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Migraine Therapeutics Market Share by Application: 2023 VS 2030
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Household Use Case Studies
Figure 12. Others Case Studies
Figure 13. Migraine Therapeutics Report Years Considered
Figure 14. Global Migraine Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Migraine Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Migraine Therapeutics Market Share by Region: 2023 VS 2030
Figure 17. Global Migraine Therapeutics Market Share by Players in 2023
Figure 18. Global Top Migraine Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Migraine Therapeutics as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Migraine Therapeutics Revenue in 2023
Figure 20. North America Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Migraine Therapeutics Market Share by Country (2019-2030)
Figure 22. United States Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Migraine Therapeutics Market Share by Country (2019-2030)
Figure 26. Germany Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Migraine Therapeutics Market Share by Region (2019-2030)
Figure 34. China Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Migraine Therapeutics Market Share by Country (2019-2030)
Figure 42. Mexico Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Migraine Therapeutics Market Share by Country (2019-2030)
Figure 46. Turkey Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Migraine Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Allergan Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 49. Merck Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 50. Pfizer Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 51. Teva Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 52. Amgen Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 53. Johnson & Johnson Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 54. Endo International Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 55. GlaxoSmithKline Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 56. Impax Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 57. Abbott Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 58. Bayer Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 59. Eli Lilly Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 60. Novartis International Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 61. Ethypharm Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 62. Kowa Pharmaceuticals America Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 63. Winston Pharmaceuticals Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 64. AstraZeneca Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 65. Amirall Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 66. OptiNose Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 67. Revance Therapeutics Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 68. RedHill Biopharma Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 69. Bausch Health Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 70. NeurAxon Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 71. Biohaven Pharma Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 72. Eisai Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 73. Valeant Pharma Revenue Growth Rate in Migraine Therapeutics Business (2019-2024)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
